Fecal Microbiota Transplantation and Microbial Therapeutics for the Treatment of Clostridioides difficile Infection in Pediatric Patients. (17th November 2021)

• Record Type: Journal Article
• Authors: Bernard, Rachel; Hourigan, Suchitra K; Nicholson, Maribeth R
• Is Part Of: Journal of the Pediatric Infectious Diseases Society. Volume 10:(2021)supplement 3
• Page Start: S58
• Page End: S63
• Publication Date: 2021-11-17
• Subjects: fecal microbiota transplantation -- fecal transplantation -- pediatric Clostridioides difficile; Communicable diseases in children -- Periodicals; Children -- Diseases -- Periodicals; 618.929
• DOI: 10.1093/jpids/piab056
• Languages: English
• ISSNs: 2048-7193

Abstract

Abstract: Clostridioides difficile infection (CDI) is the most common cause of antibiotic-associated diarrhea and has high rates of recurrent disease. As a disease associated with intestinal dysbiosis, gastrointestinal microbiome manipulation and fecal microbiota transplantation (FMT) have evolved as effective, although relatively unregulated therapeutics and not without safety concerns. FMT for the treatment of CDI has been well studied in adults with increasing data reported in children. In this review, we discuss the current body of literature on the use of FMT in children including effectiveness, safety, risk factors for a failed FMT, and the role of FMT in children with comorbidities. We also review emerging microbial therapeutics for the treatment of rCDI. Abstract : The safety and effectiveness of FMT in adults are well studied with growing data in children. As such, we review the current literature investigating the role of FMT in children and discuss emerging microbial therapeutics for recurrent Clostridioides difficile infection.